STAQ Pharma, Inc.
STAQ Pharma, Inc. appears in FDA public data with 6 recalls — including 2 Class I (most serious) —, 0 510(k) clearances, 2 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0024-2026, Class III) was initiated on October 9, 2025.
Summary
- Total Recalls
- 6 (2 Class I)
- 510(k) Clearances
- 0
- Inspections
- 2
- Compliance Actions
- 0
Recent Recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0024-2026 | Class III | Ketamine Hydrochloride, 50mg/5 mL (10mg/mL), Injection for IV use, 50 mL syringe, STAQ Pharma Inc., | October 9, 2025 |
| D-0023-2026 | Class III | Hydromorphone HCL PF, 10mg/50 mL (0.2mg/mL) in NACL, Injection for IV use, 50 mL Syringe, STAQ Pharm | October 9, 2025 |
| D-0025-2026 | Class III | FentaNYL Citrate PF, 500mcg/50 mL (10mcg/mL) in NACL, Injection for IV use, 50 mL syringe, STAQ Phar | October 9, 2025 |
| D-0147-2024 | Class II | ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg/500 mL (2 mg per mL) Injection, 500 mL bags, Rx | November 29, 2023 |
| D-0633-2022 | Class I | HYDROmorphone HCl PF 10 mg/50 mL (0.2mg/mL) in NaCl, 50 mL in 50 mL Single Dose Syringe, Rx only, ST | February 3, 2022 |
| D-0634-2022 | Class I | Morphine Sulfate PF 25 mg/25mL (1 mg/mL) in NaCl, 25 mL in 30 mL Single Dose Syringe, Rx only, STAQ | February 3, 2022 |